<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790582</url>
  </required_header>
  <id_info>
    <org_study_id>28.013</org_study_id>
    <nct_id>NCT00790582</nct_id>
  </id_info>
  <brief_title>A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>Lithium</acronym>
  <official_title>A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forbes Norris MDA/ALS Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Muscular Dystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Forbes Norris MDA/ALS Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is&#xD;
      to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the&#xD;
      progression of the disease. Since there is no placebo in this study, all patients will be&#xD;
      taking lithium carbonate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II Screening study. There is no placebo (inactive or 'fake' drug) in this&#xD;
      study, meaning that all participants will be taking lithium carbonate. The purpose of this&#xD;
      study is to find out if lithium carbonate is safe to be used in people with ALS and if it can&#xD;
      slow the progression of the disease.&#xD;
&#xD;
      A recent article was published in a highly regarded medical journal that showed a positive&#xD;
      effect of lithium carbonate on an ALS type mouse. The researchers then studied a very small&#xD;
      number of people with ALS, giving 16 people lithium carbonate with riluzole and giving 28&#xD;
      people only riluzole. The people who took lithium remained stronger for a considerably longer&#xD;
      period of time. However, the study was very small and we cannot really tell if lithium works&#xD;
      unless a larger study is performed. It is not well understood why lithium carbonate might be&#xD;
      helpful but it is believed that it may play a role in protecting the motor nerves from the&#xD;
      damage of ALS.&#xD;
&#xD;
      If you choose to participate, you will need to go to your study clinic for research study&#xD;
      visits 7 times in one year and you will have 4 telephone interviews during that time. These&#xD;
      visits and phone calls could take up to 17 hours in total.&#xD;
&#xD;
      Caution: Lithium is an FDA approved drug used for some psychiatric disorders. It is not FDA&#xD;
      approved for ALS. Lithium has many potentially serious side effects and must only be taken&#xD;
      under close supervision of your physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Monthly Rate of Decline in ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Score - Revised)</measure>
    <time_frame>Baseline, Month 1,3,4.5,6,7.5,9,10.5,12,13</time_frame>
    <description>This questionnaire has 12 questions about the patient's ability to complete certain daily activities. There are three questions each about the mouth area, arms, legs, and breathing. A normal score is 48 with each question scored at 0 (worst) to 4 (normal function). In research studies, the change in slope is measured in number of points changed per month. Maximum possible=48 (normal) Minimum=0 (severe dysfunction)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital Capacity</measure>
    <time_frame>Screen, Baseline, Month 1,3,6,9,12</time_frame>
    <description>Vital Capacity (VC) is a breathing test in which the patient is asked to take a deep breath and then blow out all of the breath through a tube. The volume is measured in number of liters. It is converted to a percent predicted for the patient's age, height, and gender.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>lithium carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lithium carbonate</intervention_name>
    <description>The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.</description>
    <arm_group_label>lithium carbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of laboratory-supported probable, probable, or definite ALS&#xD;
&#xD;
          -  Vital capacity of at least 75% of predicted&#xD;
&#xD;
          -  Onset of weakness within 3 years prior to enrollment&#xD;
&#xD;
          -  If patients are on riluzole, they must be on a stable dose for at least 30 days prior&#xD;
             to baseline visit&#xD;
&#xD;
          -  Women of childbearing potential must be surgically sterile or using an effective&#xD;
             method of birth control and have a negative pregnancy test&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of other neurodegenerative disease&#xD;
&#xD;
          -  Need tracheotomy ventilation or non-invasive ventilation 23 or more hours/day&#xD;
&#xD;
          -  Clinically significant history of any unstable medical condition in past 30 days&#xD;
&#xD;
          -  History of renal&#xD;
&#xD;
          -  History of liver disease&#xD;
&#xD;
          -  Current pregnancy or lactation&#xD;
&#xD;
          -  Use of lithium within thirty days of enrollment&#xD;
&#xD;
          -  Significantly limited mental capacity&#xD;
&#xD;
          -  History of recent drug or alcohol abuse&#xD;
&#xD;
          -  Use of any investigational drug within 30 days prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert G Miller, MD</last_name>
    <role>Study Director</role>
    <affiliation>California Pacific Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Neuromuscular Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine MDA/ALS &amp; Neuromuscular Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Department of Neurology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence ALS Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Neurological Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Clinical Neurosciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G, Spalloni A, Bellio N, Lenzi P, Modugno N, Siciliano G, Isidoro C, Murri L, Ruggieri S, Paparelli A. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2052-7. doi: 10.1073/pnas.0708022105. Epub 2008 Feb 4. Erratum in: Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16404-7.</citation>
    <PMID>18250315</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>February 3, 2011</results_first_submitted>
  <results_first_submitted_qc>October 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2020</results_first_posted>
  <last_update_submitted>October 24, 2020</last_update_submitted>
  <last_update_submitted_qc>October 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Forbes Norris MDA/ALS Research Center</investigator_affiliation>
    <investigator_full_name>Dr. Robert Miller</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Lou Gehrig's Disease</keyword>
  <keyword>Lithium</keyword>
  <keyword>Lithium Carbonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled between May 2008 and February 2009. Inclusion criteria were a diagnosis of probable or definite ALS (12), age 21-85 years, forced vital capacity (FVC) greater than or equal to 75% of predicted, and onset of weakness within 3 years. Patients taking riluzole were on a stable dose for at least 30 days.</recruitment_details>
      <pre_assignment_details>This was an open label single-arm Phase II screening trail. All enrolled subjects (n=109) were treated. Their results were compared with placebo subjects from an historical database of ALS placebo patients from recent studies (n=249). Thus the number enrolled (n=109) does not equal the total number of subjects (n=358).&#xD;
Enrolled subjects started lithium carbonate at 150 mg twice daily. If subjects did not tolerate a dose it was tapered by 150 mg increments to the maximum tolerated dosage.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>109 subjects were assigned to treatment with lithium carbonate</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>249 placebo subjects from previous clinical trials</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lithium Carbonate</title>
        </group>
        <group group_id="B2">
          <title>Historical Controls</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="249"/>
            <count group_id="B3" value="358"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="11.7"/>
                    <measurement group_id="B2" value="57.6" spread="11.0"/>
                    <measurement group_id="B3" value="57.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Monthly Rate of Decline in ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Score - Revised)</title>
        <description>This questionnaire has 12 questions about the patient's ability to complete certain daily activities. There are three questions each about the mouth area, arms, legs, and breathing. A normal score is 48 with each question scored at 0 (worst) to 4 (normal function). In research studies, the change in slope is measured in number of points changed per month. Maximum possible=48 (normal) Minimum=0 (severe dysfunction)</description>
        <time_frame>Baseline, Month 1,3,4.5,6,7.5,9,10.5,12,13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lithium Carbonate</title>
          </group>
          <group group_id="O2">
            <title>Historical Controls</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Monthly Rate of Decline in ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Score - Revised)</title>
          <description>This questionnaire has 12 questions about the patient's ability to complete certain daily activities. There are three questions each about the mouth area, arms, legs, and breathing. A normal score is 48 with each question scored at 0 (worst) to 4 (normal function). In research studies, the change in slope is measured in number of points changed per month. Maximum possible=48 (normal) Minimum=0 (severe dysfunction)</description>
          <units>points per month</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" lower_limit="1.04" upper_limit="1.35"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.90" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Capacity</title>
        <description>Vital Capacity (VC) is a breathing test in which the patient is asked to take a deep breath and then blow out all of the breath through a tube. The volume is measured in number of liters. It is converted to a percent predicted for the patient's age, height, and gender.</description>
        <time_frame>Screen, Baseline, Month 1,3,6,9,12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lithium Carbonate</title>
            <description>Treatment arm</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Capacity</title>
          <description>Vital Capacity (VC) is a breathing test in which the patient is asked to take a deep breath and then blow out all of the breath through a tube. The volume is measured in number of liters. It is converted to a percent predicted for the patient's age, height, and gender.</description>
          <units>Decline in the percent predicted/month</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" lower_limit="2.36" upper_limit="3.32"/>
                    <measurement group_id="O2" value="2.91" lower_limit="2.59" upper_limit="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded for the duration of the trial (1 year).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lithium Carbonate</title>
          <description>Treated Patients</description>
        </group>
        <group group_id="E2">
          <title>Historical Controls</title>
          <description>Placebo Patients</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="109"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="109"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="109"/>
                <counts group_id="E2" events="51" subjects_affected="51" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="63" subjects_affected="46" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ears, Nose, Throat</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" events="151" subjects_affected="86" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine/Metabolic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="109"/>
                <counts group_id="E2" events="406" subjects_affected="138" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" events="170" subjects_affected="85" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="109"/>
                <counts group_id="E2" events="209" subjects_affected="98" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Falls</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" events="194" subjects_affected="72" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" events="83" subjects_affected="56" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" events="109" subjects_affected="64" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" events="123" subjects_affected="76" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" events="211" subjects_affected="99" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Giovanna Kushner</name_or_title>
      <organization>Forbes Norris MDA/ALS Center</organization>
      <phone>415-600-3983</phone>
      <email>kushneg@cpmcri.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

